Nixon Peabody LLP

  • People
  • Capabilities
  • Insights
  • About

Trending Topics

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni

    Practices

    View All

    • Affordable Housing
    • Community Development Finance
    • Corporate & Finance
    • Cybersecurity & Privacy
    • Environmental
    • Franchising & Distribution
    • Government Investigations & White Collar Defense
    • Healthcare
    • Intellectual Property
    • International Services
    • Labor & Employment
    • Litigation
    • Private Wealth & Advisory
    • Project Finance
    • Public Finance
    • Real Estate
    • Regulatory & Government Relations

    Industries

    View All

    • Cannabis
    • Consumer
    • Energy
    • Entertainment
    • Financial Services
    • Healthcare
    • Higher Education
    • Infrastructure
    • Manufacturing
    • Non Profit
    • Real Estate
    • Technology

    Value-Added Services

    View All

    • Alternative Fee Arrangements

      Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.

    • Continuing Education

      Advancing professional knowledge and offering credits for attorneys, staff and other professionals.

    • Crisis Advisory

      Helping clients respond correctly when a crisis occurs.

    • DEI Strategic Services

      Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.

    • eDiscovery

      Leveraging law and technology to deliver sound solutions.

    • Global Services

      Delivering seamless service through partnerships across the globe.

    • Innovation

      Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.

    • IPED

      Industry-leading conferences focused on affordable housing, tax credits, and more.

    • Legal Project Management

      Providing actionable information to support strategic decision-making.

    • Legally Green

      Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.

    • Nixon Peabody Trust Company

      Offering a range of investment management and fiduciary services.

    • NP Capital Connector

      Bringing together companies and investors for tomorrow’s new deals.

    • NP Second Opinion

      Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.

    • NP Trial

      Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.

    • Social Impact

      Creating positive impact in our communities through increasing equity, access, and opportunity.

    1. Home
    2. Insights
    3. Articles
    4. New COVID vaccination requirements for travel to the USArticles

    Article

    New COVID vaccination requirements for travel to the US

    Oct 18, 2021

    Share

    By Jason Gerrol

    Effective November 8, 2021, the various country-specific travel restrictions will be replaced with a requirement for all travelers to provide proof of full COVID vaccination.

    Effective November 8, 2021, the Biden administration will allow fully vaccinated foreign travelers to enter the US via air travel and land borders, according to the White House assistant press secretary. The new travel rules will replace the various country-specific travel restrictions issued pursuant to Presidential Proclamation (PP) 9984 (China), PP 9992 (Iran), PP 10143 (Schengen Area, U.K., Ireland, Brazil, and South Africa), and PP 10199 (India) with a requirement that all travelers to the US, regardless of geographic location, provide proof of full COVID-19 vaccination, and proof of a negative COVID-19 test (taken within three days of boarding a flight to the US), prior to travel to the US.

    While the Biden administration has yet to issue full details of the new travel rules, it is understood that only vaccines that are approved by the Food and Drug Administration (FDA) or listed for emergency use by the World Health Organization (WHO) will be accepted for travelers seeking entry to the US:

    1. WHO approved: Moderna, Johnson & Johnson, Pfizer-BioNTech, Oxford-AstraZeneca/Covishield, Sinophram, and Sinovac
    2. FDA approved: Moderna, Johnson & Johnson, and Pfizer-BioNTech

    Limited exceptions will be available for children too young to receive the vaccine, COVID-19 vaccine clinical trial participants, as well as humanitarian reasons for travelers who lack access to the vaccination (although such travelers may be required to obtain the vaccination after arrival). US Citizens and Lawful Permanent Residents are exempt from the vaccination requirement, but if not vaccinated, will be required to provide proof of a negative COVID test (from a test taken within one day of departure), and proof they have purchased a viral test to be taken after arrival in the US. All travelers will be subject to a Contact Tracing Order that will require airlines to collect contact information for every passenger and provide that information to the Centers for Disease Control and Prevention (CDC) upon request.

    For land and ferry border crossings from Canada and Mexico, the Department of Homeland Security (DHS) will allow non-essential travel to the US for fully vaccinated travelers effective November 8, 2021. DHS will continue to allow “essential travel” across the Canadian and Mexican borders for unvaccinated travelers. However, in early January 2022, DHS will require all travelers across the Canadian and Mexican borders to be fully vaccinated.

    Importantly, foreign national travelers who previously received a National Interest Exception to the country-specific travel restrictions are not exempt from the requirement to provide proof of full COVID-19 vaccination effective November 8, 2021.

    Practices

    Immigration
    The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.

    Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    • © 2023 Nixon Peabody. All rights reserved
    • Privacy Policy
    • Terms of Use
    • Statement of Client Rights
    • Supplier Diversity Program
    • Nixon Peabody International LLC
    • PAL